Please ensure Javascript is enabled for purposes of website accessibility

Why Fluidigm Stock Surged Today

By Joe Tenebruso - Aug 26, 2020 at 1:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA authorized the biological research equipment maker's new coronavirus test for emergency use.

What happened 

Shares of Fluidigm (FLDM 2.35%) soared on Wednesday after the biotechnology tools provider said its new saliva-based test for SARS‑CoV‑2 -- the virus that causes COVID-19 -- received emergency use authorization from the U.S. Food and Drug Administration (FDA). As of 1:13 a.m. EDT, Fluidigm's stock was up more than 35%.

So what

Since it uses saliva samples, Fluidigm's test is easier to perform for medical professionals -- and far more comfortable for patients -- than tests that require nasal swabs. Yet Fluidigm said its test, called the Advanta Dx SARS-CoV-2 RT-PCR Assay, generated results that were in 100% agreement with the results from paired nasal-swab samples tested with other FDA-authorized assays.

A person wearing gloves is placing a swab in a test tube.

Investors are excited about the market potential of Fluidigm's new coronavirus test. stock Image source: Getty Images.

Additionally, Fluidigm said its test has production advantages that will ease the strain on the healthcare industry's supply chains. Its Biomark HD platform can produce as many as 6,000 test results per day on a single system.

"We have seen extraordinarily strong customer interest in our high-throughput saliva-based test, including many new purchases of Biomark HD systems to enable its adoption," Fluidigm CEO Chris Linthwaite said in a press release. "We have a high degree of confidence that this new test will not only enhance testing capacity but will also significantly improve speed to results and scale."

Now what

Fluidigm's assay is not the only saliva-based coronavirus test that's been authorized for emergency use by the FDA. A diagnostic test created by the Yale School of Public Health and funded in part by the NBA was granted an emergency use authorization earlier this month. Moreover, Yale's test is expected to cost only about $10 per sample. 

Still, with COVID-19 case counts continuing to rise in the U.S. and around the world, there will likely be room for multiple diagnostic options. For its part, Fluidigm expects to see strong and sustained demand for its assay. "In the United States, Emergency Use Authorization for our test coincides with the total number of COVID-19 cases exceeding 5.7 million, underscoring the need for scalable and easy-to-administer testing," Linthwaite said.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fluidigm Corporation Stock Quote
Fluidigm Corporation
FLDM
$1.74 (2.35%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.